Literature DB >> 32696303

Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.

Adriana C Gamboa1, Rachel M Lee1, Michael K Turgeon1, Mohammad Y Zaidi1, Charles W Kimbrough2, Travis E Grotz3, Jennifer Leiting3, Keith Fournier4, Andrew J Lee4, Sean P Dineen5, Benjamin D Powers5, Jula Veerapong6, Joel M Baumgartner6, Callisia N Clarke7, Harveshp Mogal7, Sameer H Patel8, Tiffany C Lee8, Laura A Lambert9, Ryan J Hendrix9, Daniel E Abbott10, Courtney Pokrzywa10, Mustafa Raoof11, Oliver S Eng12, Fabian M Johnston13, Jonathan Greer13, Jordan M Cloyd2, Shishir K Maithel14, Charles A Staley1.   

Abstract

BACKGROUND: Postoperative complications (POCs) are associated with worse oncologic outcomes in various cancer histologies. The impact of POCs on the survival of patients with appendiceal or colorectal cancer after cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is unknown.
METHODS: The US HIPEC Collaborative (2000-2017) was reviewed for patients who underwent CCR0/1 CRS/HIPEC for appendiceal/colorectal cancer. The analysis was stratified by noninvasive appendiceal neoplasm versus invasive appendiceal/colorectal adenocarcinoma. The POCs were grouped into infectious, cardiopulmonary, thromboembolic, and intestinal dysmotility. The primary outcomes were overall survival (OS) and recurrence-free survival (RFS).
RESULTS: Of the 1304 patients, 33% had noninvasive appendiceal neoplasm (n = 426), and 67% had invasive appendiceal/colorectal adenocarcinoma (n = 878). In the noninvasive appendiceal cohort, POCs were identified in 55% of the patients (n = 233). The 3-year OS and RFS did not differ between the patients who experienced a complication and those who did not (OS, 94% vs 94%, p = 0.26; RFS, 68% vs 60%, p = 0.15). In the invasive appendiceal/colorectal adenocarcinoma cohort, however, POCs (63%; n = 555) were associated with decreased 3-year OS (59% vs 74%; p < 0.001) and RFS (32% vs 42%; p < 0.001). Infectious POCs were the most common (35%; n = 196). In Multivariable analysis accounting for gender, peritoneal cancer index (PCI), and incomplete resection (CCR1), infectious POCs in particular were associated with decreased OS compared with no complication (hazard ratio [HR] 2.08; p < 0.01) or other types of complications (HR, 1.6; p < 0.01). Similarly, infectious POCs were independently associated with worse RFS (HR 1.61; p < 0.01).
CONCLUSION: Postoperative complications are associated with decreased OS and RFS after CRS/HIPEC for invasive histology, but not for an indolent disease such as noninvasive appendiceal neoplasm, and this association is largely driven by infectious complications. The exact mechanism is unknown, but may be immunologic. Efforts must target best practices and standardized prevention strategies to minimize infectious postoperative complications.

Entities:  

Year:  2020        PMID: 32696303      PMCID: PMC7988818          DOI: 10.1245/s10434-020-08843-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.

Authors:  Kevin M Turner; Mackenzie C Morris; Aaron M Delman; Dennis Hanseman; Fabian M Johnston; Jonathan Greer; Kara Vande Walle; Daniel E Abbott; Mustafa Raoof; Travis E Grotz; Keith Fournier; Sean Dineen; Jula Veerapong; Ugwuji Maduekwe; Anai Kothari; Charles A Staley; Shishir K Maithel; Laura A Lambert; Alex C Kim; Jordan M Cloyd; Gregory C Wilson; Jeffrey J Sussman; Syed A Ahmad; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2022-10-18       Impact factor: 3.267

2.  The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis.

Authors:  Oleksandr Vadymovych Bondar; Serhii Hennadiiovych Chetverikov; Viacheslav Yevheniiovych Maksymovskyi; Dmytro Vadymovych Atanasov; Valeriia Volodymyrivna Chetverikova-Ovchynnyk; Mykhailo Serhiiovych Chetverikov
Journal:  Contemp Oncol (Pozn)       Date:  2021-12-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.